Company intelligence / Profile preview

CEVEC Pharmaceuticals

Cologne, North Rhine-Westphalia, Germanycytivalifesciences.com ↗

Ownership: Private
Employees: ~46
Development stage: Commercial

Overview

CEVEC specializes in advanced cell technology platforms for scalable manufacturing of gene therapy vectors, vaccines, and complex proteins. Its core platforms are used commercially for production of adeno-associated virus (AAV) and adenoviral vectors, and for contract development, but it develops only early preclinical pipeline products itself. Company clinical trials have been at proof-of-concept/preclinical stages.

Therapeutic areas: OtherNeurology
Modalities: Gene therapyVaccineRecombinant proteinMonoclonal antibodyViral vectorBiologic
Industry: Contract Manufacturing Organization

Partnerships

Catalent Pharma SolutionsUCB

Beyond the preview

Go deeper on CEVEC Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CEVEC Pharmaceuticals.

Explore the full profile